Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06947850 · ClinicalTrials.gov registry record · Phase 4
DOMPE -MT Neurotrophic Keratitis
A Phase 4 study of Dry Eye and Neurotrophic Keratitis, sponsored by Toyos Clinic.
- Active
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06947850 is a Phase 4 study of Dry Eye and Neurotrophic Keratitis that is active but no longer recruiting, run by Toyos Clinic. The registered enrollment target is 10 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06947850, a Phase 4 study of Dry Eye and Neurotrophic Keratitis, is active but no longer recruiting, sponsored by Toyos Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis
Conditions Studied
Interventions
- DRUG Cenegermin Ophthalmic Solution [Oxervate]
Study Locations (1)
Tennessee
- Toyos Clinic - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-01-21 |
| Est. Completion | 2025-09-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06947850
The ClinicalTrials.gov registry entry for NCT06947850 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (89% lower). The listed sponsor is Toyos Clinic, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Cenegermin Ophthalmic Solution [Oxervate] is the first listed.
NCT06947850 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06947850 about?
NCT06947850 is a clinical study titled "DOMPE -MT Neurotrophic Keratitis". TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis
What is the current status of trial NCT06947850?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2023-01-21. Estimated completion is 2025-09-25.
What conditions does trial NCT06947850 study?
This clinical trial studies the following conditions: Dry Eye, Neurotrophic Keratitis.
What interventions are being tested in trial NCT06947850?
The interventions under investigation include: Cenegermin Ophthalmic Solution [Oxervate] (DRUG).
Who is sponsoring clinical trial NCT06947850?
This trial is sponsored by Toyos Clinic, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06947850 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
Performance of Systane PRO Versus Refresh Optive Mega-3
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.